Development of imiquimod-loaded mucoadhesive films for oral dysplasia

Journal of Pharmaceutical Sciences

Volumn 102, Issue 2, 2013, Pages 593-603

  Ramineni, Sandeep K ^a   Cunningham, Larry L ^b   Dziubla, Thomas D ^a   Puleo, David A ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b UNIVERSITY OF KENTUCKY COLLEGE OF DENTISTRY   (United States)

Author keywords

2 hydroxypropyl cyclodextrin; Biomaterials; Carboxymethylcellulose; Controlled release delivery; Mucosal drug delivery; Oral cancer; Polymeric drug carrier; Polyvinylpyrrolidone; Solubility

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ACETIC ACID; CARBOXYMETHYLCELLULOSE; COPOLYMER; IMIQUIMOD; LINOLEIC ACID; POLY(ETHYLENE CO VINYLACETIC ACID); POVIDONE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; COMPLEX FORMATION; CONTROLLED STUDY; CYTOKINE RELEASE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SOLUBILITY; DYSPLASIA; FILM; HYDROPHOBICITY; INTERMETHOD COMPARISON; MORPHOLOGY; MUCOADHESIVE FILM; NON INVASIVE PROCEDURE; ORAL DYSPLASIA; PRECANCER; SUSTAINED DRUG RELEASE; ULTRASOUND; WATER CONTENT;

EID: 84872456115     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23386     Document Type: Article

References (39)

1. American Cancer Society. 2012. Cancer facts and figures. Accessed November 14, 2012, at: http://www.cancer.org/Research/CancerFactsFigures/CancerFactsFigures/cancer-facts-figures-2012.
2. Neville BW, Day AT. 2002. Oral cancer and precancerous lesions. CA Cancer J Clin 52(4):195-215.
3. Shah D, Gaud RS, Misra AN, Parikh R. 2010. Formulation of a water soluble mucoadhesive film of lycopene for treatment of leukoplakia. Int J Pharm Sci Rev Res 2(1):article 002.
4. O'Neill VJ, Twelves CJ. 2002. Oral cancer treatment: Developments in chemotherapy and beyond. Br J Cancer 87(9):933-937.
5. Donnelly RF, McCarron PA, Zawislak AA, Woolfson AD. 2006. Design and physicochemical characterisation of a bioadhesive patch for dose-controlled topical delivery of imiquimod. Int J Pharm 307(2):318-325.
6. Desai KG, Mallery SR, Holpuch AS, Schwendeman SP. 2011. Development and in vitro-in vivo evaluation of fenretinide-loaded oral mucoadhesive patches for site-specific chemoprevention of oral cancer. Pharm Res 28(10):2599-2609.
7. Geisse J, Caro I, Lindholm J, Golitz L, Stampone P, Owens M. 2004. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: Results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 50(5):722-733.
8. Jr Mayeaux EJ, Rosen T, Nelson AL. 2009. Imiquimod: A comprehensive therapy. Female Patient 34(4 Suppl 1):S1-S12.
9. van Seters M, van Beurden M, ten Kate FJ, Beckmann I, Ewing PC, Eijkemans MJ, Kagie MJ, Meijer CJ, Aaronson NK, Kleinjan A, Heijmans-Antonissen C, Zijlstra FJ, Burger MP, Helmerhorst TJ. 2008. Treatment of vulvar intraepithelial neoplasia with topical imiquimod. N Engl J Med 358(14):1465-1473.
10. Chakrabarty AK, Mraz S, Geisse JK, Anderson NJ. 2005. Aphthous ulcers associated with imiquimod and the treatment of actinic cheilitis. J Am Acad Dermatol 52(2 Suppl 1 ):35-37.
11. Choi JW, Choi M, Cho KH. 2009. A case of erythroplasia of queyrat treated with imiquimod 5% cream and excision. Ann Dermatol 21(4):419-422.
12. Spieth K, Kovacs A, Wolter M, Bug R, Kaufmann R, Gille J. 2006. Topical imiquimod: Effectiveness in intraepithelial melanoma of oral mucosa. Lancet Oncol 7(12):1036-1037.
13. Allam JP, Erdsach T, Wenghoefer M, Bieber T, Appel TR, Novak N. 2008. Successful treatment of extensive human papillomavirus-associated oral leucoplakia with imiquimod. Br J Dermatol 158(3):644-646.
14. Ahuja A, Ali J, Khar KR. 1997. Mucoadhesive drug delivery systems. Drug Dev Ind Pharm 23:489-515.
15. Chowdary KP, Nalluri BN. 2000. Nimesulide and beta-cyclodextrin inclusion complexes: Physicochemical characterization and dissolution rate studies. Drug Dev Ind Pharm 26(11):1217-1220.
16. Higuchi T, Connors KA. 1965. Phase solubility techniques. Adv Anal Chem Instrum 4:117-120.
17. Wong CF, Yuen KH, Peh KK. 1999. An in-vitro method for buccal adhesion studies: Importance of instrument variables. Int J Pharm 180(1):47-57.
18. Jones DS, Bruschi ML, de Freitas O, Gremiao MP, Lara EH, Andrews GP. 2009. Rheological, mechanical and mucoadhesive properties of thermoresponsive, bioadhesive binary mixtures composed of poloxamer 407 and carbopol 974P designed as platforms for implantable drug delivery systems for use in the oral cavity. Int J Pharm 372(1-2):49-58.
19. Luo K, Yin J, Khutoryanskaya OV, Khutoryanskiy VV. 2008. Mucoadhesive and elastic films based on blends of chitosan and hydroxyethylcellulose. Macromol Biosci 8(2):184-192.
20. Averineni RK, Sunderajan SG, Mutalik S, Nayak U, Shavi G, Armugam K, Meka SR, Pandey S, Nayanabhirama U. 2009. Development of mucoadhesive buccal films for the treatment of oral sub-mucous fibrosis: A preliminary study. Pharm Dev Technol 14(2):199-207.
21. Perioli L, Ambrogi V, Angelici F, Ricci M, Giovagnoli S, Capuccella M, Rossi C. 2004. Development of mucoadhesive patches for buccal administration of ibuprofen. J Control Release 99(1):73-82.
22. Ganjian S, Ourian AJ, Shamtoub G, Wu JJ, Murase JE. 2009. Off-label indications for imiquimod. Dermatol Online J 15(5):4.
23. Galey WR, Lonsdale HK, Nacht S. 1976. The in vitro permeability of skin and buccal mucosa to selected drugs and tritiated water. J Invest Dermatol 67(6):713-717.
24. Gates KA, Grad H, Birek P, Lee PI. 1994. A new bioerodible polymer insert for the controlled release of metronidazole. Pharm Res 11(11):1605-1609.
25. Shidhaye SS, Saindane NS, Sutar S, Kadam V. 2008. Mucoadhesive bilayered patches for administration of sumatriptan succinate. AAPS PharmSciTech 9(3):909-916.
26. Chollet JL, Jozwiakowski MJ, Phares KR, Reiter MJ, Roddy PJ, Schultz HJ, Ta QV, Tomai MA. 1999. Development of a topically active imiquimod formulation. Pharm Dev Technol 4(1):35-43.
27. Patwardhan AM, Akopian AN, Ruparel NB, Diogenes A, Weintraub ST, Uhlson C, Murphy RC, Hargreaves KM. 2010. Heat generates oxidized linoleic acid metabolites that activate TRPV1 and produce pain in rodents. J Clin Invest 120(5):1617-1626.
28. Stella VJ, Rajewski RA. 1997. Cyclodextrins: Their future in drug formulation and delivery. Pharm Res 14(5):556-567.
29. Uekama K, Hirayama F, Irie T. 1998. Cyclodextrin drug carrier systems. Chem Rev 98(5):2045-2076.
30. Szejtli J. 1998. Introduction and general overview of cyclodextrin chemistry. Chem Rev 98(5):1743-1754.
31. Monnaert V, Tilloy S, Bricout H, Fenart L, Cecchelli R, Monflier E. 2004. Behavior of alpha-, beta-, and gamma-cyclodextrins and their derivatives on an in vitro model of blood-brain barrier. J Pharmacol Exp Ther 310(2):745-751.
32. Halim Mohamed MA, Mahmoud AA. 2011. Formulation of indomethacin eye drops via complexation with cyclodextrins. Curr Eye Res 36(3):208-216.
33. Baboota S, Dhaliwal M, Kohli K. 2005. Physicochemical characterization, in vitro dissolution behavior, and pharmacodynamic studies of rofecoxib-cyclodextrin inclusion compounds. preparation and properties of rofecoxib hydroxypropyl beta-cyclodextrin inclusion complex: A technical note. AAPS PharmSciTech 6(1):E83-E90.
34. Doiphode D, Gaikwad S, Pore Y, Kuchekar B, Late S. 2008. Effect of β-cyclodextrin complexation on physicochemical properties of zaleplon. J Incl Phenom Macrocycl Chem 62(1):43-50.
35. Liu J, Qiu L, Gao J, Jin Y. 2006. Preparation, characterization and in vivo evaluation of formulation of baicalein with hydroxypropyl-beta-cyclodextrin. Int J Pharm 312(1-2):137-143.
36. Beraldo H, Sinisterra RD, Teixeira LR, Vieira RP, Doretto MC. 2002. An effective anticonvulsant prepared following a host-guest strategy that uses hydroxypropyl-beta-cyclodextrin and benzaldehyde semicarbazone. Biochem Biophys Res Commun 296(2):241-246.
37. Muzio G, Ciambellotti A, Rebora A. 2004. Occlusive medication with imiquimod in Bowen's disease. Acta Derm Venereol 84(2):168-169.
38. Sterry W, Ruzicka T, Herrera E, Takwale A, Bichel J, Andres K, Ding L, Thissen MR. 2002. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: Randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol 147(6):1227-1236.
39. Food Drug Administration. 2012. Guidance for industry Q3C-Tables and list. Accessed November 14, 2012, at: http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm128282.pdf%20.